Clinical Trial Update: A Study of (LY3650150) Lebrikizumab to Assess the Safety and Efficacy of Adult and Adolescent Participants With Moderate-to-Severe Atopic Dermatitis and Skin of Color [Phase 3]

View source ↗

Summary

Phase 3 clinical trial update for Lebrikizumab (LY3650150) in adults and adolescents with moderate-to-severe Atopic Dermatitis; trial completed with results pos…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Atopic Dermatitis

Drugs mentioned

• Lebrikizumab (LY3650150) (Lebrikizumab)

Snippet

Sponsor: Eli Lilly and Company | Conditions: Atopic Dermatitis | Phase 3 | Status: COMPLETED | Results posted: 2025-06-11